Literature DB >> 23473895

Clinical validation and implementation of a multiplexed immunosuppressant assay in dried blood spots by LC-MS/MS.

Katerina Sadilkova1, Barbara Busby, Jane A Dickerson, Joe C Rutledge, Rhona M Jack.   

Abstract

BACKGROUND: Therapeutic drug monitoring of immunosuppressive drugs is important in transplant patients. We developed and validated liquid chromatography-mass spectrometry (LC-MS/MS) assay for simultaneous quantitation of tacrolimus (TaC), sirolimus (SrL), and cyclosporin A (CsA) in dried blood spots (DBSs) to offer patients home sample collection, avoiding travel for blood draws.
METHODS: After extraction, samples were analyzed by LC-MS/MS in multiple reaction monitoring mode.
RESULTS: The assay was linear between 1.2-40 ng/ml for TaC and SrL, and 30-1000 ng/ml for CsA. Inter- and intra-assay CVs were ≤14.8% for all 3 drugs. This method correlated well with the existing clinical whole blood assay, with coefficients of determination >0.95 for all 3 drugs. DBS quality control samples were stable for at least 30 days at -20, 4, and 25°C. Stability of patient DBS samples was at least 5 days at temperatures up to 60°C, except for SrL where degradation was observed at 60°C within 24 h. No effect of hematocrit level, blood spot volume or punch location was observed.
CONCLUSION: Immunosuppressant levels measured in DBS correlate with whole blood LC-MS/MS assay and may contribute to successful outcome of organ transplant and patient satisfaction.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23473895     DOI: 10.1016/j.cca.2013.02.009

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

Review 1.  Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS.

Authors:  Mwlod Ghareeb; Fatemeh Akhlaghi
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

2.  Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device.

Authors:  Tom C Zwart; Sumit R M Gokoel; Paul J M van der Boog; Johan W de Fijter; Dina M Kweekel; Jesse J Swen; Henk-Jan Guchelaar; Dirk Jan A R Moes
Journal:  Br J Clin Pharmacol       Date:  2018-10-15       Impact factor: 4.335

3.  Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS.

Authors:  Touraj Shokati; Nicholas Bodenberger; Holly Gadpaille; Björn Schniedewind; Alexander A Vinks; Wenlei Jiang; Rita R Alloway; Uwe Christians
Journal:  J Vis Exp       Date:  2015-11-08       Impact factor: 1.355

Review 4.  Therapeutic drug monitoring by dried blood spot: progress to date and future directions.

Authors:  Abraham J Wilhelm; Jeroen C G den Burger; Eleonora L Swart
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

5.  Advantages and Challenges of Dried Blood Spot Analysis by Mass Spectrometry Across the Total Testing Process.

Authors:  Rosita Zakaria; Katrina J Allen; Jennifer J Koplin; Peter Roche; Ronda F Greaves
Journal:  EJIFCC       Date:  2016-12-01

6.  Validation of a simple liquid chromatography coupled to tandem mass spectrometry method for the simultaneous determination of tacrolimus, sirolimus, everolimus and cyclosporin A in dried matrix on paper discs.

Authors:  Ignacio Guillermo Bressán; María Isabel Giménez; Susana Francisca Llesuy
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2021-02-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.